Again, a slightly but significantly positive correlation between TRIM66 and IL‐2 was observed in the clinical prostate tumor database (Fig. 4C, P < 0.01), which was consolidated by the down‐regulation of IL‐2 at both transcript (Fig. 4D) and protein (Fig. 4E) levels in TRIM66‐deficient PC‐3 cells. This evidence concerns the gene IL2 and prostate neoplasm.